Publications by authors named "Trygve Sundby Hall"
Article Synopsis
- The study assessed the relationship between frailty, illness severity, and survival rates after hospital discharge in older adults admitted with acute illnesses.
- Using data from 195 participants (average age 86), researchers measured frailty using the Clinical Frailty Scale and illness severity with the New Early Warning Score 2 and a laboratory index, tracking survival for 20 months post-discharge.
- Findings indicated that higher frailty and illness severity scores were linked to decreased post-discharge survival, with frailty having a greater impact on survival in patients with more severe illnesses.
Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins.
Noreen Butt Lena K Bache-Mathiesen Jan Erik Nordrehaug Vegard Tuseth Peter Scott Munk Trygve Sundby Hall
Cardiology
August 2018
Objectives: In the MITOCARE study, reperfusion injury was not prevented after administration of the mitochondrial permeability transition pore (mPTP) opening inhibitor, TRO40303, in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). The effects of TRO40303 on pro-inflammatory cytokines and acute-phase proteins were assessed.
Methods: STEMI patients (n = 163, mean age 62 years) with chest pain within 6 h before admission for pPCI were randomized to intravenous bolus of TRO40303 (n = 83) or placebo (n = 80) prior to reperfusion.